Collaboration to Supply Antiviral Drug Standards to Assist in COVID-19 Research Announced

Through a commercial partnership with Alsachim, Cambridge Isotope Labs (CIL) is proud to now offer an assortment of unlabelled and stable isotope-labelled antiviral drug standards and their metabolites to assist in COVID-19 research and therapy development.  

“We are thrilled to join forces with CIL in order to answer US customers’ needs and deliver crucial compounds for COVID-19 therapeutic monitoring,” said Dr Jean-Francois Hoeffler, President of Alsachim.

CIL, the largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds, is now collaborating with Alsachim to provide antiviral drug standards to researchers and clinicians exclusively in the Americas. These products are available through CIL in convenient packaging sizes and are adept for use as internal standards in therapeutic monitoring and quantitative analysis. 

Alsachim, expert in the research and development of unique stable isotope-labelled compounds, has synthesised internal standards necessary for the monitoring of potential treatments being tested for COVID-19, such as remdesivir, hydroxychloroquine, and favipiravir. Alsachim has increased its research activities and its production capacities in order to supply these standards to hospitals and research facilities globally.

CIL’s Vice President of Sales and Marketing Maureen Duffy added: “We are excited to partner with Alsachim to offer their high-quality drug standards to provide a much-needed service to those US pharmaceutical and biotech companies that are actively pursuing therapies to treat COVID-19.”

Through this affiliation, CIL and Alsachim will enhance worldwide coverage to provide researchers critical reagents to perform cutting-edge science in an effort to defeat the coronavirus pandemic.  

More information online